Transthyretin cardiac amyloidosis is a serious progressive disease that was until recently considered untreatable. In recent years, however, new treatment options targeting the underlying pathology of the disease have emerged, which, along with advances in non-invasive diagnostics, offer patients hope for a longer and better-quality life.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
